Skip to main content
SKINBIOTHERAPEUTICS PLC logo

SKINBIOTHERAPEUTICS PLC — Investor Relations & Filings

Ticker · SBTX ISIN · GB00BF33H870 LEI · 213800YMQOCB23FX6I06 IL Manufacturing
Open in API
Filings indexed 315 across all filing types
Latest filing 2024-03-18 Major Shareholding Noti…
Country GB United Kingdom
Listing IL SBTX

About SKINBIOTHERAPEUTICS PLC

https://www.skinbiotherapeutics.com/

SkinBioTherapeutics PLC is a life science company focused on advancing skin health by harnessing the human microbiome. Its proprietary SkinBiotix® platform technology utilizes probiotic lysates to protect, manage, and restore skin. The company develops and commercializes products across several healthcare sectors, including cosmetics, food supplements, medical devices, and pharmaceuticals. Key offerings include AxisBiotix, a probiotic food supplement designed to address psoriasis symptoms, and the Dermatonics line of specialized foot care products. Through its acquisition of Bio-Tech Solutions, the company also provides formulation, manufacturing, and packaging services for healthcare, personal care, and hygiene products.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is clearly identified by the header 'RNS Number : 2571H' and contains the standard format for 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The content details the percentage change (from 13.52% to 12.94%) and the date the threshold was crossed (12/03/2024). This aligns perfectly with the 'Major Shareholding Notification' category (MRQ).
2024-03-18 English
New research project and CSO to return to academia
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 18, 2024. It announces two key pieces of information: a new research project ('Epiderm project') and a change in senior management (CSO moving to Scientific Adviser). The presence of the RNS header, the AIM listing reference, and the concluding statement about 'inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014' strongly indicate this is a regulatory news service announcement from the London Stock Exchange. Since the content primarily concerns operational updates and management changes rather than specific financial results (ER/IR) or formal shareholder voting (DVA), the most appropriate general category for a non-standard regulatory announcement is 'Regulatory Filings' (RNS). It is not a formal financial report (10-K, IR) or a specific management compensation report (DEF 14A).
2024-03-18 English
Conversion Notice and Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'Conversion Notice' related to convertible bonds, the subsequent issuance of new ordinary shares, and the resulting change in 'Total Voting Rights' (192,795,949). This type of announcement, which involves changes in share capital structure, insider transactions (though this is a bond conversion, it results in new shares), or significant corporate actions reported via the RNS system, often falls under general regulatory announcements. Since the core event is the issuance of shares following a bond conversion and the notification of the new total voting rights denominator, it relates to share capital changes and regulatory disclosure. While 'SHA' (Share Issue/Capital Change) is relevant, the document's primary function here is a formal regulatory disclosure via the RNS system regarding a specific corporate event (conversion leading to share issuance and voting rights update). Given the context of RNS distribution and the nature of the disclosure (which is not a full financial report, proxy, or earnings release), 'RNS' (Regulatory Filings) serves as the most appropriate general category for this specific type of market-sensitive announcement distributed through the LSE's primary information provider, especially when the specific event (bond conversion/share issuance) doesn't perfectly align with the narrow definitions of SHA or DIV, but is clearly a mandatory regulatory update.
2024-03-12 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is very short (3795 characters) and its primary purpose is to announce that the company's 'interim financial results for the six months to 31 December 2023 will be released on Friday 22 March 2024.' It also mentions that a presentation will follow on the same day. This structure—announcing the future publication date of a report rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it a general regulatory filing (RNS) since a more specific category applies based on the 'MENU VS MEAL' rule.
2024-03-08 English
Conversion notice and alternative financing
Capital/Financing Update Classification · 99% confidence The document is clearly identified as an 'RNS Number' release from 'SkinBioTherapeutics PLC' dated '28 February 2024'. The content discusses a 'Conversion Notice' regarding Convertible Bonds, the decision to seek 'alternative financing options', the application for admission of new ordinary shares, and the resulting 'Total Voting Rights' figure (191,687,425). This type of announcement, which details specific corporate actions, financing changes, and regulatory notifications (like the total voting rights denominator for FCA rules), is characteristic of a general regulatory news service release. Since it is not a full annual report (10-K), an earnings release (ER), a proxy statement (DEF 14A), or a specific transaction like a takeover (TAR) or share repurchase (POS), the most appropriate general category for a standard regulatory news service announcement is 'RNS'. The document length (5521 chars) is substantial enough that it is the primary announcement itself, not just a brief notice of publication (RPA).
2024-02-28 English
Positive Interim AxisBiotix Acne study results
Earnings Release Classification · 99% confidence The document is identified by the header 'RNS Number' and contains a date (27 February 2024) and company information, typical of a regulatory news service announcement from the London Stock Exchange. The content announces 'interim data' from a consumer study for an acne supplement, providing specific quantitative results in a table format and concluding with contact details and standard RNS disclaimers. This is a specific operational update or announcement, not a comprehensive annual report (10-K), a formal earnings release (ER), or a full interim report (IR). Since it is a general regulatory announcement disseminated via RNS that doesn't fit the more specific categories like DIV, DIRS, or ER, the most appropriate classification is the general regulatory filing category. Q1 2024
2024-02-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.